Piper Jaffray Companies began coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research report sent to investors on Monday. The brokerage issued an overweight rating and a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Fate Therapeutics from a buy rating to a hold rating in a research report on Wednesday, September 6th. HC Wainwright reissued a buy rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine lowered Fate Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. BMO Capital Markets restated a buy rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. Finally, Raymond James Financial restated a buy rating on shares of Fate Therapeutics in a research note on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $7.25.

Shares of Fate Therapeutics (FATE) traded up $0.17 during trading on Monday, reaching $4.36. The company had a trading volume of 411,900 shares, compared to its average volume of 299,772. Fate Therapeutics has a 1-year low of $2.40 and a 1-year high of $5.68. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.95 million. Fate Therapeutics’s revenue was up .0% on a year-over-year basis. research analysts forecast that Fate Therapeutics will post -0.99 earnings per share for the current year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of Fate Therapeutics stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of FATE. State Street Corp bought a new position in shares of Fate Therapeutics during the 2nd quarter worth approximately $1,437,000. Northern Trust Corp boosted its stake in shares of Fate Therapeutics by 968.7% during the 2nd quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after acquiring an additional 333,753 shares during the period. TIAA CREF Investment Management LLC bought a new position in shares of Fate Therapeutics during the 2nd quarter worth approximately $373,000. Vanguard Group Inc. boosted its stake in Fate Therapeutics by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock valued at $4,096,000 after purchasing an additional 108,602 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Fate Therapeutics by 164.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 157,546 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 98,036 shares during the period. Institutional investors own 60.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Fate Therapeutics (FATE) Coverage Initiated by Analysts at Piper Jaffray Companies” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/fate-therapeutics-fate-coverage-initiated-by-analysts-at-piper-jaffray-companies/1772944.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.